HomeEverythingEducation
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Concord Biotech shares jump 8% on USFDA nod for Mycophenolate Mofetil

Created at 3 Jun · 5:51 AM2 sources↑ Market-relevant2 events
IN SHORT

Concord Biotech shares rose 8% after receiving USFDA approval for its Mycophenolate Mofetil for Oral Suspension. The drug is an immunosuppressant used for organ transplant patients.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Key Numbers

8%share price jump

Who's Involved

Concord Biotech
Pharmaceutical company receiving USFDA approval
USFDA
U.S. Food and Drug Administration granting approval

↳ Why This Matters

USFDA approval allows Concord Biotech to market its Mycophenolate Mofetil for Oral Suspension in the United States, potentially boosting revenue and expanding its product portfolio in the critical organ transplant market.

Key facts

  • Concord Biotech received USFDA approval for Mycophenolate Mofetil for Oral Suspension.
  • The drug is an antimetabolite immunosuppressant used in organ transplant patients.
  • Concord Biotech shares jumped 8% following the announcement.

Concord Biotech's stock experienced an 8% increase on Wednesday after the company announced it had received approval from the U.S. Food and Drug Administration (USFDA) for its Mycophenolate Mofetil for Oral Suspension. This medication is classified as an antimetabolite immunosuppressant and is prescribed to patients who have undergone organ transplantation. The approval is a significant development for Concord Biotech, potentially opening up a new market for its pharmaceutical products in the United States. The drug's indication for use in organ transplant recipients highlights its critical role in post-transplant care.

Frequently asked questions

Mycophenolate Mofetil is an antimetabolite immunosuppressant medication used to prevent organ rejection in patients who have received an organ transplant.

USFDA approval signifies that the drug has met the agency's standards for safety and efficacy, allowing Concord Biotech to market and sell the product in the United States.

Concord Biotech's shares saw a significant jump of 8% following the announcement of the USFDA approval.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence
CME Headlines
  • New Product Summary: Initial Listing of Fifty-Five (55) Single Stock Futures Contracts — Effective July 27, 2026
    27 Jul · 4:32 PM
  • New Product Summary: Initial Listing of Twenty-Two (22) Micro Single Stock Futures Contracts - Effective July 27, 2026
    27 Jul · 4:11 PM
  • Initial Listing of Additional Event Contract Swaps on Pro Golf Tournaments
    9 Jul · 9:41 AM

How It Developed

3 Jun · 5:21 AM
The new article restates that Concord Biotech shares jumped 8% on USFDA approval for Mycophenolate Mofetil.
Economic Times via PiQSuite
3 Jun · 5:21 AM
Concord Biotech shares surged 8% after receiving USFDA approval for its Mycophenolate Mofetil oral suspension, used in organ transplant patients.
Economic Times via PiQSuite

Sources

T1
Concord Biotech jumps 8% on USFDA nod for Mycophenolate Mofetil oral suspensionm.piqsuite.com
T1
Concord Biotech shares jump 8% on USFDA nod for Mycophenolate Mofetil oral suspensionm.piqsuite.com

Related Stories

Zhipu AI Shares Rise After Lockup Expiry Amid Investor Support
8 Jul · 8:25 PM
Levi Strauss raises annual outlook on steady denim demand
8 Jul · 8:17 PM
JPMorgan Hires Michael Flynn to Lead New Small-Cap Banking Business
8 Jul · 3:03 PM
Michael Burry Buys Flutter, DraftKings Shares on Prediction Market Threat
8 Jul · 9:51 PM
Honeywell Technologies raises 2026 profit targets after reverse stock split
8 Jul · 9:08 PM